Evidence map›Paper›PMID 38098959›Full record

ArticleLeukemia research reports2023

Venetoclax monotherapy as front-line therapy for blastic plasmacytoid dendritic cell neoplasm.

Ankit Mitesh Shah, Denise Pereira, Julio Poveda, Trent Peng Wang

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia research reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ankit Mitesh ShahUniversity of Miami Miller School of Medicine, Miami, FL, USA.
Denise PereiraDivision of Transplantation & Cellular Therapy, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, 1411 NW 12th Ave, Suite 231, Miami, FL 33136, USA.
Julio PovedaDepartment of Pathology, University of Miami Miller School of Medicine, Miami, FL, USA.
Trent Peng WangDivision of Transplantation & Cellular Therapy, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, 1411 NW 12th Ave, Suite 231, Miami, FL 33136, USA.
University of Miami · US

Funding

UM Calabresi Clinical Oncology Research Career Development AwardK12CA226330 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Alan Pollack · 2018 to 2026
$5.1M
NCI NIH HHS K12 CA226330
6 · The paper itself

Abstract

Venetoclax is an approved treatment for relapsed/refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). We report a unique case of venetoclax monotherapy used for front-line induction and as a bridge to allogeneic hematopoietic stem cell transplantation (HCT). Venetoclax therapy resulted in rapid complete resolution of skin lesions, however, treatment interruption due to neutropenia led to brisk cancer recurrence. Fortunately, the patient responded to re-challenge and was able to undergo HCT. Venetoclax is active in the first-line treatment setting for BPDCN, however its effect on blood counts and durability of response should be further studied.

Indexed as

Allogeneic hematopoietic stem cell transplantationBlastic plasmacytoid dendritic cell neoplasmTargeted therapyVenetoclax

Identifiers

PMID38098959
PMCPMC10719512
OpenAlexW4382934413

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.